A33 antigen displays persistent surface expression

Cancer Immunology, Immunotherapy

Volumn 57, Issue 7, 2008, Pages 1017-1027

  Ackerman, Margaret E ^a   Chalouni, Cecile ^b   Schmidt, Michael M ^c   Raman, Vivek V ^c   Ritter, Gerd ^d   Old, Lloyd J ^d   Mellman, Ira ^b   Wittrup, K Dane ^c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

A33 antigen; Colon cancer; Immunoglobulin superfamily; Radioimmunotherapy; Tight junction

Indexed keywords

A33 ANTIBODY; A33 ANTIGEN; ANTIBODY; CELL SURFACE PROTEIN; MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL SURFACE; COLON CANCER; CONTROLLED STUDY; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTESTINE; ISOTOPE LABELING; METASTASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RADIOIMMUNOTHERAPY; SOLID TUMOR; SURFACE PROPERTY; TIGHT JUNCTION; TRANSPORT KINETICS; TURNOVER TIME;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; MEMBRANE GLYCOPROTEINS; TIGHT JUNCTIONS;

EID: 42649121968     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0433-x     Document Type: Article

References (51)

1. DeNardo GL (2005) Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 35(3):202-211
2. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW (2003) Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101(6):2340-2348
3. Gruaz-Guyon A, Raguin O, Barbet J (2005) Recent advances in pretargeted radioimmunotherapy. Curr Med Chem 12(3):319-338
4. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44(3):400-411
5. Johnstone CN, Tebbutt NC, Abud HE, White SJ, Stenvers KL, Hall NE, Cody SH, Whitehead RH, Catimel B, Nice EC, Burgess AW, Heath JK (2000) Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 279(3):G500-G510
6. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW (1997) The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 94(2):469-474
7. Garin-Chesa P, Sakamoto J, Welt S, Real FX, Rettig WJ, Old LJ (1996) Organ-specific expression of the colon cancer antigen A33, a cell suface target for antibody-based therapy. Int J Oncol 9:465-471
8. Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N et al (1990) Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 8(11):1894-1906
9. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF et al (1994) Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 12(8):1561-1571
10. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ (1996) Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 14(6):1787-1797
11. Welt S, Ritter G, Williams C Jr, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE (2003) Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 9(4):1338-1346
12. Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, Paul U, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ (2005) A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 11(13):4810-4817
13. Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, Paul U, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder TJ, O'Keefe G, Burgess AW, Hoffman EW, Old LJ, Scott AM (2005) Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 11(13):4818-4826
14. Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S (2001) Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61(18):6851-6859
15. Johnstone CN, White SJ, Tebbutt NC, Clay FJ, Ernst M, Biggs WH, Viars CS, Czekay S, Arden KC, Heath JK (2002) Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression. J Biol Chem 277(37):34531-34539
16. Chen CJ, Shively JE (2004) The cell-cell adhesion molecule carcinoembryonic antigen-related cellular adhesion molecule 1 inhibits IL-2 production and proliferation in human T cells by association with Src homology protein-1 and down-regulates IL-2 receptor. J Immunol 172(6):3544-3552
17. Ellenberg J, Siggia ED, Moreira JE, Smith CL, Presley JF, Worman HJ, Lippincott-Schwartz J (1997) Nuclear membrane dynamics and reassembly in living cells: targeting of an inner nuclear membrane protein in interphase and mitosis. J Cell Biol 138(6):1193-1206
18. Umenishi F, Verbavatz JM, Verkman AS (2000) cAMP regulated membrane diffusion of a green fluorescent protein-aquaporin 2 chimera. Biophys J 78(2):1024-1035
19. Partikian A, Olveczky B, Swaminathan R, Li Y, Verkman AS (1998) Rapid diffusion of green fluorescent protein in the mitochondrial matrix. J Cell Biol 140(4):821-829
20. Le TL, Yap AS, Stow JL (1999) Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics. J Cell Biol 146(1):219-232
21. Ji H, Moritz RL, Reid GE, Ritter G, Catimel B, Nice E, Heath JK, White SJ, Welt S, Old LJ, Burgess AW, Simpson RJ (1997) Electrophoretic analysis of the novel antigen for the gastrointestinal-specific monoclonal antibody, A33. Electrophoresis 18(3-4):614-621
22. Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham MC, McGuffie E, Old LJ, Larson SM (1996) Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med 37(6):1052-1057
23. Bruewer M, Utech M, Ivanov AI, Hopkins AM, Parkos CA, Nusrat A (2005) Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. Faseb J 19(8):923-933
24. Kevil CG, Oshima T, Alexander B, Coe LL, Alexander JS (2000) H(2)O(2)-mediated permeability: role of MAPK and occludin. Am J Physiol Cell Physiol 279(1):C21-C30
25. Harhaj NS, Antonetti DA (2004) Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 36(7):1206-1237
26. Musch MW, Walsh-Reitz MM, Chang EB (2006) Roles of ZO-1, occludin, and actin in oxidant-induced barrier disruption. Am J Physiol Gastrointest Liver Physiol 290(2):G222-G231
27. Ivanov AI, Nusrat A, Parkos CA (2004) Endocytosis of epithelial apical junctional proteins by a clathrin-mediated pathway into a unique storage compartment. Mol Biol Cell 15:176-188
28. Mandell KJ, Parkos CA (2005) The JAM family of proteins. Adv Drug Deliv Rev 57(6):857-867
29. Gray-Owen SD, Blumberg RS (2006) CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 6(6):433-446
30. Kostrewa D, Brockhaus M, D'Arcy A, Dale GE, Nelboeck P, Schmid G, Mueller F, Bazzoni G, Dejana E, Bartfai T, Winkler FK, Hennig M (2001) X-ray structure of junctional adhesion molecule: structural basis for homophilic adhesion via a novel dimerization motif. Embo J 20(16):4391-4398
31. Brummendorf T, Lemmon V (2001) Immunoglobulin superfamily receptors: cis-interactions, intracellular adapters and alternative splicing regulate adhesion. Curr Opin Cell Biol 13(5):611-618
32. Walters RW, Freimuth P, Moninger TO, Ganske I, Zabner J, Welsh MJ (2002) Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 110(6):789-799
33. Mullin JM, Agostino N, Rendon-Huerta E, Thornton JJ (2005) Keynote review: epithelial and endothelial barriers in human disease. Drug Discov Today 10(6):395-408
34. Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, Chiba H (2003) Tight junctions and human diseases. Med Electron Microsc 36(3):147-156
35. Mullin JM (2004) Epithelial barriers, compartmentation, and cancer. Sci STKE 2004(216):pe2
36. Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM (1999) Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 20(8):1425-1431
37. Ivanov AI, McCall IC, Babbin B, Samarin SN, Nusrat A, Parkos CA (2006) Microtubules regulate disassembly of epithelial apical junctions. BMC Cell Biol 7:12
38. Furuse M, Itoh M, Hirase T, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S (1994) Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol 127(6):1617-1626
39. Li Y, Fanning AS, Anderson JM, Lavie A (2005) Structure of the conserved cytoplasmic C-terminal domain of occludin: identification of the ZO-1 binding surface. J Mol Biol 352:151-164
40. Cliffe A, Mieszczanek J, Bienz M (2004) Intracellular shuttling of a Drosophila APC tumour suppressor homolog. BMC Cell Biology 5:37
41. Thomas T, Jordan K, Simek J, Shao Q, Jedeszko C, Walton P, Laird DW (2005) Mechanisms of Cx43 and Cx26 transport to the plasma membrane and gap junction regeneration. J Cell Sci 119:4451-4462
42. Kirshner J, Schumann D, Shively JE (2003) CEACAM1, a cell-cell adhesion molecule, directly associates with annexin II in a three-dimensional model of mammary morphogenesis. J Biol Chem 278(50):50338-50435
43. Schumann D, Chen CJ, Kaplan B, Shively JE (2001) Carcinoembryonic antigen cell adhesion molecule 1 directly associates with cytoskeleton proteins actin and tropomyosin. J Biol Chem 276(50):47421-47433
44. Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9(2):67-81
45. Chretien I, Marcuz A, Courtet M, Katevuo K, Vainio O, Heath JK, White SJ, Du Pasquier L (1998) CTX, a Xenopus thymocyte receptor, defines a molecular family conserved throughout vertebrates. Eur J Immunol 28(12):4094-4104
46. Bazzoni G (2003) The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 15(5):525-530
47. Kuespert K, Pils S, Hauck CR (2006) CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 18:565-571
48. van Osdol W, Fujimori K, Weinstein JN (1991) An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res 51(18):4776-4784
49. Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH, Weinstein JN (1995) Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 92(19):8999-9003
50. Graff CP, Wittrup KD (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 63(6):1288-1296
51. Thurber GM, Zajic SC, Wittrup KD (2007) Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48(6):995-999